Skip to main content
Marcus Svensson Frej on Muck Rack

Marcus Svensson Frej

As seen in: medRxiv, The Journal of Clinical Investigation
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Marcus Svensson

Contact Marcus Svensson, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Safety and feasibility of blood-derived Multiple Antigen-Specific Endogenous T cells (MASE-T) for metastatic melanoma

|
By Marcus Svensson Frej, Cecilie Lund Vestergaard, Tine Juul Monberg, Siri Amanda Tvingsholm
| medRxiv
TJM, SAT, MSF, CV, MO, JWK, RBH, NJ, JSG, SKL and OM declares no competing interests. THB has received personal payment for lectures/presentation from Bristol Myers Squibb. ARC is co-founder of PokeAcell, developer of the Ag-scaffold technology and has stokcs or stock options in PokeAcell and Cymab. SRH is co-inventor of two patents related to the Ag-scaffold technology (EP 16205918.2 and 18178769.8) filled and owned by the Technical University of Denmark.
Open in Who Shared Issue with article?

T antigen–specific CD8+ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma

|
By Ulla Kring Hansen, Candice Church, Marcus Svensson Frej, Amalie Kai Bentzen
| The Journal of Clinical Investigation
Abstract Merkel cell carcinoma (MCC) is a highly immunogenic skin cancer primarily induced by Merkel cell polyomavirus, which is driven by the expression of the oncogenic T antigens (T-Ags). Blockade of the programmed cell death protein-1 (PD-1) pathway has shown remarkable response rates, but evidence for therapy-associated T-Ag–specific immune response and therapeutic strategies for the nonresponding fraction are both limited.
Open in Who Shared Issue with article?
See all 2 articles